Study for HER2-positive bladder cancer after limited treatment
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have urothelial cancer that is locally advanced/unresectable or metastatic (cannot be removed by surgery).
- Your tumor is HER2-positive (IHC 1+, 2+, or 3+) based on a central lab test of tumor tissue.
- You have at least one measurable tumor spot on scan that the study doctor can track (RECIST 1.1).
- Your general functioning score (ECOG) is usually 0–1, or sometimes up to 2 depending on the cohort.
- You must have had the right amount/type of prior treatment for your cohort (for example, 0, 1–2 lines, or specific drugs like platinum, PD-(L)1, or enfortumab vedotin).
- You should not have had recent major treatment or lingering side effects above mild levels (typically must be back to Grade 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
This trial tests a targeted therapy (disitamab vedotin, also called RC48) given directly into the bladder after surgery for HER2-positive upper tract urothelial cancer. The goal is to see if it helps prevent the cancer from coming back.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.